In addition, chemokine CXC receptor (CXCR), vascular cell adhesion molecule 1 (VCAM1), and E-selectin ligands have been assessed to cover MSC surfaces to aid their targeted delivery to wounded sites, improving the therapeutic results of IBD therapy [35, 37]. This evidence concerns the gene VCAM1 and inflammatory bowel disease.